Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

value

- PMLiVE

Winning the war against cancer

Dr Josep Figueras on survival, access to treatments and the need for good data in oncology

- PMLiVE

New philosophies driving transformative healthcare

The key trends and philosophies driving this disruptive and innovative era of healthcare forward

- PMLiVE

Trump talks pricing and manufacturing with pharma

Heads of Celgene, Lilly, Merck & Co, Novartis and trade body PhRMA met at the White House

- PMLiVE

The reality of real-world evidence

Despite a slow uptake of RWE, there is an increasing trend in the use of healthcare system data to inform clinical practice

Smart connections with a human touch

Simon Young, Director at Blue Latitude Health, discusses how advances in technology are influencing the future of the expert-patient relationship and why healthcare businesses must evaluate how best to support...

Blue Latitude Health

- PMLiVE

Managed Access Programmes: a powerful source of real-world insight

MAPs represent a unique opportunity to gather evidence from a cohort of patients receiving the same treatment, across multiple countries prospectively before launch

- PMLiVE

Real-world evidence

Companies are now recruiting high-level executives to lead well-resourced RWE teams as industry looks to reshape the future

UK flag

Life sciences to play key role in UK’s post-Brexit strategy

Prime minister unveils plans to boost jobs, growth and commercialise country’s science base

- PMLiVE

A rare talent

Shire’s Sebastian Stachowiak on dealing with change and working for a fit-for-purpose orphan drug environment

- PMLiVE

The impact of Trump’s victory on pharma and healthcare

Donald Trump’s presidency is unlikely to leave any industry untouched. But how will pharma, biotech and healthcare fare when he takes office?

UK flag

May says UK’s science base is a “negotiating priority” for Brexit

Stokes confidence in UK pharma as science and innovation featured among 12 key priorities

Market access in Europe: balancing access and affordability

European governments continue to pursue national agendas for market access, while also exploring opportunities to work together to achieve lower prices for new drugs

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links